Does oral prednisone reduce symptoms in upper and lower respiratory tract infections in otherwise healthy adults?

Oral Prednisone Should NOT Be Used for Upper or Lower Respiratory Tract Infections in Otherwise Healthy Adults

Oral prednisone does not reduce symptom duration or severity in acute respiratory tract infections and should not be prescribed for this indication. The evidence is clear and consistent across multiple high-quality guidelines and a definitive randomized controlled trial.

Evidence Against Prednisone Use

Lower Respiratory Tract Infections (Acute Bronchitis)

The 2017 OSAC trial—the highest quality and most recent evidence—definitively demonstrated that oral prednisolone (40 mg daily for 5 days) provided no benefit for acute lower respiratory tract infection in adults without asthma 1. Among 398 patients:

• Cough duration: No difference between groups (median 5 days in both arms; adjusted HR 1.11,95% CI 0.89-1.39, P=0.36)
• Symptom severity: No clinically meaningful difference (adjusted difference -0.20 points on 0-6 scale, below the minimal clinically important difference of 1.66 units)
• No benefit for any secondary outcomes including other symptom duration, peak flow abnormalities, or antibiotic use

Importantly, a 2020 exploratory analysis of this same trial specifically examined patients with clinically unrecognized asthma (those with wheeze and nocturnal symptoms suggesting possible asthma) and found no benefit even in this subgroup 2.

The 2016 ACP/CDC guidelines explicitly state that symptomatic therapy—not corticosteroids—is appropriate for acute bronchitis 3. The French guidelines similarly note that "prescription of NSAIDs at an anti-inflammatory dose level or of systemic corticosteroids is not justified" for acute bronchitis in healthy adults 4.

Upper Respiratory Tract Infections

For acute rhinosinusitis, the 2016 ACP/CDC guidelines recommend intranasal corticosteroids (not oral) as adjunctive therapy, primarily for symptom relief 3. The 2012 IDSA guidelines and 2015 AAO-HNS guidelines support intranasal corticosteroids as adjuncts but make no recommendation for oral corticosteroids 5, 6.

For the common cold, guidelines recommend symptomatic therapy only—antibiotics and corticosteroids are not indicated 3.

For pharyngitis, one small 2005 trial (n=60) showed that 60 mg prednisone for 1-2 days reduced throat pain duration 7. However, this single small study from a general practice in Israel has not been replicated in larger trials or incorporated into major guidelines. The benefit was modest and short-term pain relief only—not addressing the underlying infection.

Critical Safety Concerns

The FDA drug label for prednisone explicitly warns that corticosteroids 8:

• Suppress the immune system and increase infection risk with any pathogen
• Can reduce resistance to new infections
• Can exacerbate existing infections
• Can mask signs of infection
• Increase risk of disseminated infections
• Can reactivate latent tuberculosis, hepatitis B, and strongyloides

Long-term follow-up data from pneumonia trials show that corticosteroid use is associated with:

• Increased recurrent pneumonia (OR 2.57,95% CI 1.29-5.12) 9
• Increased secondary infections (OR 1.94,95% CI 1.25-3.03) 9
• New insulin dependence (OR 8.73,95% CI 1.10-69.62) 9

Clinical Algorithm

For acute bronchitis/lower respiratory tract infection:

1. Confirm no pneumonia (absence of tachycardia >100 bpm, tachypnea >24/min, fever >38°C, and abnormal chest exam) 3
2. Do NOT prescribe oral corticosteroids
3. Offer symptomatic relief: cough suppressants, expectorants, first-generation antihistamines, decongestants as needed 3
4. Advise symptoms may last up to 2 weeks

For acute rhinosinusitis:

1. Reserve antibiotics for persistent symptoms >10 days or severe symptoms 3
2. Consider intranasal corticosteroids (not oral) for symptom relief 3, 5, 6
3. Offer analgesics, saline irrigation, decongestants as needed

For common cold:

1. Symptomatic therapy only
2. No role for oral corticosteroids 3

Common Pitfalls to Avoid

• Do not prescribe oral prednisone thinking it will shorten illness duration—it won't 1
• Do not use oral steroids as a substitute for antibiotics in respiratory infections
• Do not assume patients with wheezing or nocturnal symptoms will benefit—they don't 2
• Distinguish intranasal from oral corticosteroids—only intranasal steroids have a role in rhinosinusitis as adjunctive therapy
• Remember the immunosuppressive risks outweigh any theoretical anti-inflammatory benefits in self-limited viral infections

The evidence is unequivocal: oral prednisone has no role in treating upper or lower respiratory tract infections in otherwise healthy adults and carries meaningful risks of infection complications.